PFS Partners’s ProQR Therapeutics PRQR Stock Holding History

PFS Partners’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.62K	Hold	1,000	–	–	﹤0.01%	531
2025 Q4	$2.02K	Hold	1,000	–	–	﹤0.01%	516
2025 Q3	$2.13K	Hold	1,000	–	–	﹤0.01%	501
2025 Q2	$2.04K	Hold	1,000	–	–	﹤0.01%	461
2025 Q1	$1.33K	Hold	1,000	–	–	﹤0.01%	404
2024 Q4	$2.65K	Hold	1,000	–	–	﹤0.01%	385
2024 Q3	$1.82K	Hold	1,000	–	–	﹤0.01%	404
2024 Q2	$1.66K	Hold	1,000	–	–	﹤0.01%	397
2024 Q1	$2.29K	Hold	1,000	–	–	﹤0.01%	413
2023 Q4	$1.98K	Hold	1,000	–	–	﹤0.01%	412
2023 Q3	$1.3K	Hold	1,000	–	–	﹤0.01%	420
2023 Q2	$1.62K	Hold	1,000	–	–	﹤0.01%	432
2023 Q1	$2.13K	Hold	1,000	–	–	﹤0.01%	326
2022 Q4	$3.7K	Buy	+1,000	New	+$1.31K	﹤0.01%	282

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

PFS Partners's PRQR Position: Q1 2026 in Review

PFS Partners held its ProQR Therapeutics (PRQR) position steady in Q1 2026 at 1,000 shares worth $1.62K. The position accounts for ﹤0.01% of the portfolio, ranked #531.

PFS Partners first reported a position in PRQR in Q4 2022 and has held it in 14 quarters since. The position peaked at $3.7K in Q4 2022. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

PFS Partners held 1,000 shares of ProQR Therapeutics worth $1.62K as of Q1 2026.
PFS Partners left its ProQR Therapeutics share count unchanged in Q1 2026.
ProQR Therapeutics made up ﹤0.01% of PFS Partners's portfolio in Q1 2026, its #531 holding.
PFS Partners first reported a position in ProQR Therapeutics in Q4 2022 and has held it in 14 quarters since.
PFS Partners's ProQR Therapeutics position peaked at $3.7K in Q4 2022.
69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on PFS Partners's 13F filing for Q1 2026, filed 9 Apr 2026.